Huntsman Cancer Institute Deininger | O'Hare Lab

Selected Publications

Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.
Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, Kovacsovics TJ, Marth GT, O'Hare T, Deininger MW. Leukemia. 2018 Mar 27. doi: 10.1038/s41375-018-0050-z. PMID: 29588547

Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.
Patel AB, Lange T, Pomicter AD, Conley CJ, Harrington CA, Reynolds KR, Kelley TW, O'Hare T, Deininger MW. Oncotarget. 2018 Apr 3;9(25):17889-17894 doi: 10.18632/oncotarget.24954. PMID: 29707154

Autocrine TNF signaling favors malignant cells in myelofibrosis in a TNFR2-dependent fashion.
Heaton WL, Senina AV, Pomicter AD, Salama ME, Clair PM, Yan D, Bell RN, Gililland JM, Prchal JT, O'Hare T, Deininger MW. Leukemia. 2018 Apr 18. doi: 10.1038/s41375-018-0131-z. PMID: 29749399 

A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia.
Zabriske MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, O'Hare T. Haematologica. 2018 Feb;103(2):e87-e91. doi: 10.3324/haematol.2017.165282. Epub 2017 Dec 28.

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, O'Hare T. Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.264.PMID:28819281

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia
MS Zabriskie, CA Eide, D Yan, NA Vellore, AD Pomicter, SL Savage, BJ Druker, MW Deininger, T O'Hare. Leukemia (2016) 30, 1418-1421; doi:10.1038/leu.2015.318; published online 8 December 2015. PMID:26582647, PMCID:PMC4873472

Age-related mutations and chronic myelomonocytic leukemia.
Mason CC*, Khorashad JS*, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL,Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, O'Hare T, Deininger MW.
Leukemia. 2016 Apr;30(4):906-13. doi: 10.1038/leu.2015.337. Epub 2015 Dec 9.

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.
Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, O'Hare T, Deininger MW.
Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.196. [Epub ahead of print]. PMID: 26202934.

Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, O'Hare T, Deininger MW.
Exp Hematol. 2015 Jul;43(7):537-545.e11. doi: 10.1016/j.exphem.2015.03.006. Epub 2015 Apr 24.
PMID:25912019

Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T.
Leukemia. 2015 Feb 13. doi: 10.1038/leu.2015.42. [Epub ahead of print].
PMID:25676420

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, O'Hare T, Deininger MW.
Blood. 2015 Mar 12;125(11):1772-81. doi: 10.1182/blood-2014-08-588855. Epub 2015 Jan 8.
PMID:25573989
See commentary.

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.
Eiring AM, Deininger MW.
Genome Biol. 2014 Sep 17;15(9):461. doi: 10.1186/s13059-014-0461-8.
PMID:25316524

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW. Leukemia, published online August 19, 2014

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D,Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A,Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. New England Journal of Medicine. 2013 Nov 7;369(19):1783-96.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW. Cancer Research. 2013 Sep 15;73(18):5775-86.

New concepts for CML clonality. Khorashad JS, Deininger MW, O'Hare T. Oncotarget. 2013 Jan;4(1):7-8.

Ponatinib in refractory Philadelphia chromosome-positive leukemias. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. New England Journal of Medicine. 2012 Nov 29;367(22):2075-88.

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CMLAgarwal A, Fleischman AG, Petersen CL, Mackenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW. Blood. 2012 Sep 27;120(13):2658-68. Epub 2012 Aug 13.

Pushing the limits of targeted therapy in chronic myeloid leukemiaO'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Nature Reviews Clinical Oncology. 2012 Jul 24;12(8):513-26.

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitorsTraer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, Druker BJ, Deininger MW. Leukemia. 2012 May;26(5):1140-3.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasmsFleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW. Blood. 2011 Dec 8;118(24):6392-8. Epub 2011 Aug 22.

Curing CML with imatinib—a dream come true?
Deininger, M. Nature Reviews Clinical Oncology. 8, 127–128 (2011); published online 1 February 2011; doi:10.1038/nrclinonc.2011.17

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, O'Brien SG, Melo JV, Lange T, Harrington CA, Deininger MW. Blood. 2010 Jan 14;115(2):315-25. Epub 2009 Oct 16.

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. Blood. 2010 Oct 28;116(17):3278-85. Epub 2010 Jun 2.

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW. Blood. 2010 Jun 24;115(25):5232-40. Epub 2010 Apr 12.

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia.
Zabriskie MS, Eide CA, et al.
Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.
Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM.
Cancer Res. 2013 Jan 1;73(1):285-96.

Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M.
N Engl J Med. 2012 Nov 29;367(22):2075-88.

Pushing the limits of targeted therapy in chronic myeloid leukaemia.
O'Hare T, Zabriskie MS, Eiring AM, Deininger MW.
Nat Rev Cancer. 2012 Jul 24;12(8):513-26. Review.

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R.
Cancer Cell. 2011 Dec 13;20(6):715-27.

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J.
Cancer Cell. 2010 Jul 13;18(1):74-87.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T.
Cancer Cell. 2009 Nov 6;16(5):401-12.

PubMed, Michael Deininger

PubMed, Thomas O'Hare